FuboTV To Lose Some CBS Affiliates Monday
-The Streamable
https://thestreamable.com/news/fubotv-will-lose-some-cbs-affiliates-monday-how-to-keep-watching
China’s Top Nuclear-Weapons Lab Used American Computer Chips, Including Chips From Intel And Nvidia, Decades After Ban
-Wall Street Journal
https://www.wsj.com/articles/chinas-top-nuclear-weapons-lab-used-american-computer-chips-decades-after-ban-11674990320
Report of Explosion At Military Plant In Iran’s Central City Of Isfahan Caused By A Drone Attack
-Reuters Citing Iranian State Media
Luminar Eyes Building Factory For Lidar Sensors In Asia
-Nikkei
https://asia.nikkei.com/Business/Technology/U.S.-s-Luminar-eyes-building-factory-for-lidar-sensors-in-Asia
Eindhovens Dagblad Reported Earlier Philips Is Announcing Another Radical Reorganization On Monday, Including Further Job Cuts
https://www.ed.nl/economie/weer-klap-bij-philips-alleen-al-in-nederland-zouden-meer-dan-duizend-banen-worden-geschrapt~aa3382ae/
Bloomberg Reported Thursday, Fidelity Cut Ant Group Valuation By 9% To $64B
https://www.bloomberg.com/news/articles/2023-01-27/fidelity-cuts-ant-group-valuation-by-another-9-to-64-billion?sref=y3YMCJ4e&leadSource=uverify%20wall
Reuters Reported Thursday Senator Debbie Stabenow Blocked Bid Thursday By Joe Manchin To Pass A Measure That Would Block Some EVs From Receiving $7,500 Tax Credit
https://www.reuters.com/business/autos-transportation/us-senator-blocks-bid-close-ev-tax-window-2023-01-27/
Regeneron, Sanofi Announced Earlier , Dupixent Recommended For Expanded EU Approval By The CHMP To Treat Children As Young As Six Months Old With Severe Atopic Dermatitis
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent® (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy.
European Medicines Agency Accepted Marketing Authorization Application For Lecanemab As Treatment For Early Alzheimer’s Disease
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody[1], for the treatment of Early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD)